HC Wainwright Cuts Earnings Estimates for Sage Therapeutics

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Analysts at HC Wainwright reduced their FY2028 EPS estimates for Sage Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings of $0.50 per share for the year, down from their previous forecast of $0.56. HC Wainwright currently has a “Neutral” rating and a $14.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.43) per share.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. During the same quarter last year, the company posted ($2.81) earnings per share. The company’s revenue was up 337.1% on a year-over-year basis.

Several other research firms also recently commented on SAGE. Needham & Company LLC restated a “hold” rating on shares of Sage Therapeutics in a research note on Wednesday. The Goldman Sachs Group decreased their price target on shares of Sage Therapeutics from $19.00 to $11.00 and set a “neutral” rating on the stock in a research note on Friday, July 26th. Bank of America decreased their price target on shares of Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating on the stock in a research note on Wednesday, October 9th. Truist Financial cut their price objective on shares of Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $26.00 price objective (down previously from $52.00) on shares of Sage Therapeutics in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.89.

Sage Therapeutics Stock Performance

SAGE stock opened at $6.05 on Thursday. The company’s 50-day simple moving average is $7.44 and its 200 day simple moving average is $9.95. Sage Therapeutics has a 52 week low of $5.84 and a 52 week high of $28.26. The company has a market capitalization of $370.10 million, a PE ratio of -1.08 and a beta of 0.91.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Headlands Technologies LLC raised its holdings in Sage Therapeutics by 245.3% in the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 2,782 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Sage Therapeutics by 66.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after buying an additional 4,672 shares during the last quarter. Creative Planning bought a new position in Sage Therapeutics in the 3rd quarter valued at approximately $88,000. Lazard Asset Management LLC bought a new position in Sage Therapeutics in the 1st quarter valued at approximately $127,000. Finally, Quest Partners LLC raised its holdings in Sage Therapeutics by 14.5% in the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after buying an additional 1,486 shares during the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.